Recipharm

Recipharm

Tillverkning av läkemedel

Stockholm, Stockholm County 80 445 följare

Your innovation, delivered with certainty.

Om oss

Recipharm is an experienced, global CDMO dedicated to meeting pharmaceutical companies’ evolving needs through operational excellence, scientific know-how and customer connectivity. Headquartered in Stockholm, Sweden, we operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering. Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together. With a workforce of approximately 9,000 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. For over 25 years we’ve supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.

Webbplats
http://www.recipharm.com
Bransch
Tillverkning av läkemedel
Företagsstorlek
5 001–10 000 anställda
Huvudkontor
Stockholm, Stockholm County
Typ
Privatägt företag
Specialistområden
Pharmaceutical contract development and manufacturing, Commercial manufacturing, Analytical chemistry, Drug substance och Drug product development

Adresser

Anställda på Recipharm

Uppdateringar

  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    WEBINAR | Listen to our expert speakers Yves Buelens, Jean-Christophe Moreau and Christophe Schwoehrer explain blow-fill-seal (BFS) technology and the unique benefits of unidose BFS for ophthalmics, biologics and other sterile drug products. Webinar learning objectives: 1. What is BFS technology and the unique benefits of unidose BFS 2. What are the advantages of BFS unidose format in comparison to ocular multidose or glass vial format? 3. How can a CDMO support pharma companies in switching to unidose BFS Watch on demand: https://lnkd.in/d9TRp6ZV

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    Interest in mRNA technology is higher than ever. However, there are challenges and production bottlenecks that make the scale-up of current mRNA technologies difficult. Could the development of continuous mRNA manufacturing hold the key? In a recent article for DCAT® Value Chain Insights, ReciBioPharm’s Chief Scientific Officer, Aaron B Cowley , explains how ReciBioPharm is working with MIT’s Center for Continuous mRNA Manufacturing to, in his own words, “advance RNA manufacturing far beyond what exists today in the realm of intelligent manufacturing”. Read on to find out more: https://lnkd.in/dY8YyMmD #ContinuousmRNAManufacturing #mRNA #ATMP #MIT #CenterForContinuousmRNAManufacturing

    • Ingen alternativ bildtext i den här bilden
  • Recipharm omdelade detta

    Visa profilen för Greg Behar, grafik

    CEO at Recipharm

    Pioneering Sustainability to elevate Production and Customer Service! The Recipharm Pianezza site in Italy continues to excel in environmental sustainability. I am very excited to announce that we have recently installed and validated a new line dedicated to manufacturing #anesthetic products at our #Pianezza site. Production will commence in the last quarter of the year with a couple of existing customers and more to come soon. This new line is a great example of our commitment to sustainability. By transferring the line from another site, we are not only creating capacity for customers but also reducing the environmental impact of what would have been a disused line. In addition, through collaboration with two main customers on two production lines, we have reviewed production processes which have led to: - 6% reduction in water usage - 60% reduction in greenhouse gas emissions related to these activities - Over 10% reduction in natural gas consumption - Cost savings on water and gas usage - Increased capacity on both lines We are proud of these accomplishments and look forward to continuing our journey towards greater sustainability and efficiency, especially when this means a real “win” for our customers and patients! #AnaestheticProducts #SustainabilityInPharma

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    Unlocking our sites | With 39 years of experience, our Masate facility is recognised as one of Recipharm's leading sterile manufacturing locations. Supporting over 43 markets worldwide, we take pride in manufacturing more than 80 commercial products, each adhering to the highest quality standards. Specialising in injectables, the facility offers advanced lyophilisation services and liquid filling in vials and ampoules, ensuring tailored solutions for our clients. Discover how we can meet your fill and finish needs, both today and in the future: https://lnkd.in/dTWJ7aAx #CDMO #Sterilefill #Fillfinish #Lyophilization

  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    The global biologics market is growing and developers are exploring alternative container formats for their sterile drug products. As each container format has different characteristics and advantages, careful consideration is required to optimise the performance of biologics products and deliver innovative treatments to patients. In our latest piece with BioProcess International, Vincenza Pironti, Ph.D., MBA Pironti, Head of Business Development at Recipharm explores the key considerations when selecting sterile container formats: https://lnkd.in/dsWQmk6y #BFS #PFS #Fillfinish #Biologics

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    A pioneering biotech dedicated to developing oncolytic adenovirus therapies had one year to deliver its groundbreaking flagship product to first-in-human clinical trials. Failure to do so risked potential investment consequences and could have prevented the therapy from making it to market. Find out how our experts in oncolytic viruses helped the biotech overcome critical challenges to achieving these accelerated timelines to deliver their therapy on schedule. https://lnkd.in/d7ipxhre #OncolyticViruses #RareDisease #OVManufacturing

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    Our Pianezza facility plays an important role on the journey to lowering CO2 emissions through innovative e-transport solutions together with, UCB, and their carrier, Green Logistics by Galliker We are very proud that our client chose us to take part in the test run, to transport pharmaceutical products between UCB Farchim SA in Bulle, Switzerland, and Recipharm in Pianezza, Italy, saving an impressive 842 kg of CO2 emissions. This collaboration highlights our shared commitment to reducing CO2 emissions and achieving the goals set as members of the SBT initiative. Read the full article here: https://lnkd.in/dapES4Ni https://lnkd.in/dfU6pRjv

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    EVENT | We are excited to announce that Balasubramaniam Jagdish, our Vice President of Formulation Development, will be participating in the CRS 2024 Annual Meeting and Expo, which will take place from July 8-12 in Bologna, Italy. Balasubramaniam will be presenting a poster on a case study involving a fixed-dose combination of Ciprofloxacin and Celecoxib as an investigational drug for Amyotrophic Lateral Sclerosis (ALS) patients. He will discuss how Recipharm developed a controlled-release monolithic tablet dosage form consisting of both drugs. We look forward to connecting with other professionals in the field. If you are attending the meeting, please feel free to reach out to Balasubramaniam Jagdish before or during the event. #CSR #formulationdevelopment #OSD #CDMO

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    ✨Heading to CPHI Milan?✨ We offer you a unique opportunity to visit our advanced manufacturing facilities, Masate and Pianezza for extensive site tours. 🏭Masate A leader in sterile manufacturing with 39 years of expertise, producing for over 43 markets. Specializes in advanced lyophilisation and sterile liquid filling. 🏭Pianezza Renowned for versatile manufacturing of oral liquids and extensive packaging options, including analytical services and QP release. Register today and learn how Recipharm can take your product to market! https://lnkd.in/d-qkrD3S CPHI will be held from October 8-10. It's time to start scheduling your meetings. Please contact us to arrange your meeting soon, we look forward to seeing you there! #CPHIMilan #CDMO #Fillfinish #OSD

  • Visa organisationssidan för Recipharm, grafik

    80 445 följare

    Excited to share Recipharm's cutting-edge advancements in pharma analytical services, driven by our expert team and state-of-the-art technologies across Europe and India. Join us as we continue to enhance our product development capabilities, contributing to a healthier world. 🌟 Read our CEO Greg Behar's post below 👇   #ProductDevelopment #Pharmaceuticals #Innovation #GlobalReach #ExpertTeam

    Visa profilen för Greg Behar, grafik

    CEO at Recipharm

    Showcasing Excellence: Recipharm's impressive suite of experts and instruments empower pharma innovation and drug development success. Recipharm’s dedicated product development capabilities in Europe and India are designed to serve the diverse needs of our clients. Over 150 dedicated (Masters and PhDs) scientists work with more than 100 HPLCs, 50+ dissolution apparatus, LC-MS-MS, GC-MS-MS, HRMS, ICP-MS and ICP-OES and many other modern analytical technologies, to provide cutting-edge drug development capabilities. Our Integrated Product Development Centre in India specialises in oral solid formulation development and clinical supply for Phase II & III, working with many of the top global pharma organisations supporting the development of future medicine. We work on studies supporting the development of medication for the treatment of epilepsy, bipolar disorder, migraine, multiple sclerosis, neuropathic pain, amyotrophic lateral sclerosis and many other indications. We offer integrated and stand-alone analytical services. From analytical method development, analytical method validation, pharmacopeial testing and verification, raw material and excipient testing, stability storage analysis, to nitrosamines, extractable & leachable, elemental impurities testing or identification of unknown impurities, we have it covered. Our sterile GMP small/pilot scale capabilities from our European sites support faster tech transfers with credibility and trust. We have small/pilot scale development capabilities in Blow-Fill-Seal (BFS) technology and vials, for: - Solutions, gels, suspensions, emulsions - Ophthalmic drug products, - Inhalation treatments - Sterile injectables, including vaccines and biologics. We don’t rest on our laurels: we are adding further in-formulation development capabilities at our Indian Centre of Excellence. Our European development capabilities are expanding to include pilot-scale dry/IR technologies for dispensing, blending, compaction, tableting and hard capsule filling. The investments at sites include equipment for powder characterisation as well as compaction and compression simulation for science-driven and fact-based decisions during development. Join us on this exciting journey as we continue to innovate, enhance our product development capabilities and, ultimately, contribute to a healthier world. https://lnkd.in/eSukbnfb #ProductDevelopment #Pharmaceuticals #Innovation #GlobalReach #ExpertTeam

    Pharmaceutical analytical services

    Pharmaceutical analytical services

    recipharm.com

Liknande sidor

Finansiering

Recipharm 2 rundor totalt

Senaste finansieringsrunda

Aktiekapital efter börsintroduktion

32 000 000,00 US$

Se mer info på crunchbase